



Scandinavian College of  
Neuropsychopharmacology

# SCNP Conference

# PROGRAM

## SOME OF THE TOPICS

- Major Depression ✓
- Bipolar Depression ✓
- Schizophrenia ✓
- Psychosis ✓
- ADHD ✓
- Alcohol Use Disorder ✓
- Drug Discovery ✓
- Industry perspectives ✓
- Basic and clinical research ✓



29-31 May  
GOTHENBURG - SWEDEN



Visit the website for more information

<https://www.conftool.net/scnp2024/sessions.php>

<https://scnp.org/annual-meeting/2024>





**Scandinavian College of  
Neuropsychopharmacology**

**14.00-17.00**

---

**DRUG  
DISCOVERY IN  
PSYCHIATRY –  
PATENT ISSUES**

---

**PERFORMING  
CLINICAL TRIALS  
IN PSYCHIATRY –  
INDUSTRY  
PERSPECTIVES**

---

- Bo Söderpalm, Professor,  
University of Gothenburg,  
Sweden
- Andrea Bejczy, Ph.D.,  
University of Gothenburg,  
Sweden
- Christian von Holt, Janssen  
Pharmaceuticals, Germany
- Henrik Sjölander, patent  
attorney at Barker Brettell  
Sweden AB

**WORKSHOP**

**29  
MAY**

**PLACE**

**Första  
Långgatan 16**

# SCNP meeting

30  
MAY

PLACE  
Hotel Draken



Scandinavian College of  
Neuropsychopharmacology

---

08:30 Registration and  
coffee

---

09.00 General Assembly  
09.25 (members only)

---

09.25 President's  
09.30 Welcome

- Sophie Erhardt, Professor,  
Karolinska Institutet, Sweden
  - Bo Söderpalm, Professor,  
University of Gothenburg,  
Sweden
- 

09.30 Opening Lecture  
10.15 Bipolar Depression

**Is bipolar disorder neuroprogressive?  
Insights into brain structure, cognition,  
and biomarkers from longitudinal  
investigations**

- Mikael Landén, Professor,  
University of Gothenburg,  
Sweden
- 

10.15 Coffee Break &  
10.45 Poster Session

---

# SCNP meeting

30  
MAY

PLACE

Hotel Draken



Scandinavian College of  
Neuropsychopharmacology

10.45

12.15 Alcohol Use Disorder

Is bipolar disorder neuroprogressive?  
Neurobiological mechanisms of  
compulsive alcohol use.

- Markus Heilig, Professor,  
Linköping University, Sweden

The COMB-study; a multicenter RCT on  
the effects of varenicline and bupropion in  
alcohol use disorder.

- Andrea de Bejczy, M.D., Ph.D.,  
University of Gothenburg, Sweden

Sodium oxybate: a substitution therapy  
for alcohol use disorder?

- Julien Guiraud, Ph.D.,  
Vergio Consulting

12.15 Lunch &

13.30 Poster Session

13.30 SCNP Young Scientist

15.00 Symposium

15.00 Coffee Break &

15.45 Poster Session

15.45 Depression

16.30 New treatment options in TRD:  
hope or hype?

- Andreas Reif, Professor,  
University Hospital Frankfurt,  
Germany

Paddan Tour + Dinner

# SCNP meeting

31  
MAY

PLACE  
Hotel Draken



**Scandinavian College of  
Neuropsychopharmacology**

---

**08.30**  
**10.30** ADHD

**Real-world effectiveness of ADHD medications in amphetamine dependence and borderline personality disorder**

- Milja Hartikainen, MD, PhD, Specialist in forensic psychiatry. Niuvanniemi Hospital, Finland

**ADHD drug use in Iceland and hospitalization for new-onset psychosis or mania among adults**

- Halldora Jonsdottir, Associate Professor, University of Iceland, ADHD medications and long-term risk of cardiovascular diseases
- Le Zhang, Karolinska Institutet, Sweden

---

**10.00** Coffee Break &  
**10.30** Poster Session

---

**10.30** Depression

**12.00** Novel trial designs to personalize antidepressant treatment

- Daniel Lindqvist, Associate Professor, Lund University, Sweden

**Psilocybin as an antidepressant? Clinical effect and biological correlates**

- Johan Lundberg, Adjunct Professor, Karolinska Institutet, Sweden
- Psychotropic medication and the fetal brain
- Lars-Henning Pedersen, Professor, Århus University, Denmark

# SCNP meeting

31  
MAY

PLACE  
Hotel Draken



**Scandinavian College of  
Neuropsychopharmacology**

---

**12.00 Lunch &**

**13.15 Poster Session**

---

**13.15 SCNP Lecture**

**14.00 Psychosis**

**Treatment resistance in psychotic disorders:  
Are patients not responding to medications,  
or are clinicians not responding to  
guidelines**

- Ingrid Melle, Professor, University of Oslo, Norway
- 

**14.00 Coffee Break &**

**14.30 Poster Session**

---

**14.30 Schizophrenia**  
**16.00**

**ImmunoPsychiatry – evidence from large-  
scale studies to detailed clinical studies**

- Mikael Benros, Professor,  
University of Denmark

**Add-on prednisolone vs. placebo in early  
psychotic disorders: Results of a pilot  
study.**

- Erik Johnsen, Professor, University  
of Bergen, Norway

**Studies of glial cells and synaptic markers  
in early stages of psychosis and clinical  
high-risk states**

- Simon Cervenka, Professor,  
Uppsala University, Sweden

**Endocannabinoid dysregulation in psychotic  
disorders**

- Heikki Laurikainen, MD, PhD,  
University of Turku, Finland
- 

**16.00 Closing**